"Medicaid Coverage of and Spending on GLP-1s." Tracking of state Medicaid GLP-1 coverage policies shows about a dozen states cover for obesity, with policies evolving
Multiple testing methods confirm compound identity and purity
NICE first recommended the drug in draft guidance 2022, after a clinical trial of just under 2000 volunteers found that people lost on average 12% more weight with semaglutide alongside supervised weight loss coaching (BMJ 2023;380:556)
The wide spectrum of outcomes and demographic gradients observed emphasize the urgent need for precision approaches to obesity treatment and highlight opportunities for next-generation incretin therapeutics informed by real-world response phenotypes
"The HCSC transaction closed later than the company's financial planning assumptions, increasing the first quarter Cigna Healthcare [MLR] as the Medicare businesses operate at a higher [MLR] compared to the rest of the portfolio," the company wrote in its filing
GLP-1 receptor agonists are among the most clinically significant drugs to reach mainstream use in a generation